BioSpace News Archive

Walgreens broadens digital health marketplace with 15 new or expanded national and local providers offering cancer screening, diabetes management, vision and mental health services

OBIO is pleased to announce that Dr. Maura Campbell, Vice President, Intellectual Property and Contracts, Turnstone Biologics, was appointed as Chair of the OBIO Board of Directors.

Interview of PBIO CEO Ric Schumacher Focuses on Potential Impact of Company’s Innovative UST Platform for Major Advances in Food Safety, Clean Label, Nutrition, and Long-Term Room Temperature Stability

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Conference.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright Global Life Sciences Conference, held virtually on March 9 - 10 , 2021.

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Sciences Conference which is being held from March 9th to 10th through a virtual format with on-demand video presentations.

- Broad and potent immune responses demonstrated with full length Spike protein antigen - Large animal studies and COVID variant testing planned - Facilitates development of a heat-stable vaccine candidate, avoiding refrigeration or freezing

Mevion Medical Systems announced that it has been selected to install a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning at the Levine Cancer Institute at Atrium Health in North Carolina.

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China.

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2020 financial and operating results on Thursday, March 11, 2021 before the market opens.